BIN1 in the Pursuit of Ousting the Alzheimer’s Reign: Impact on Amyloid and Tau Neuropathology

• Published in: Neurotoxicity research 2023-12, Vol.41 (6), p.698-707
• Main Authors: Kaur, Ishnoor, Behl, Tapan, Sundararajan, G., Panneerselvam, P., Vijayakumar, A. R., Senthilkumar, G. P., Venkatachalam, T., Jaglan, Dharmender, Yadav, Shivam, Anwer, Khalid, Fuloria, Neeraj Kumar, Sehgal, Aayush, Gulati, Monica, Chigurupati, Sridevi
• Format: Article
• Language: English
• Subjects: Biomedical and Life Sciences; Biomedicine; Cell Biology; Neurobiology; Neurochemistry; Neurology; Neurosciences; Pharmacology/Toxicology; Review
• ISSN: 1029-8428; 1476-3524
• DOI: 10.1007/s12640-023-00670-3

Alzheimer’s disease contributes to 60–70% of all dementia cases in the general population. Belonging to the BIN1/amphiphysin/RVS167 (BAR) superfamily, the bridging integrator (BIN1) has been identified to impact two major pathological hallmarks in Alzheimer’s disease (AD), i.e., amyloid beta (Aβ) and tau accumulation. Aβ accumulation is found to increase by BIN1 knockdown in cortical neurons in late-onset AD, due to BACE1 accumulation at enlarged early endosomes. Two BIN1 mutants, KR and PL, were identified to exhibit Aβ accumulation. Furthermore, BIN1 deficiency by BIN1-related polymorphisms impairs the interaction with tau, thus elevating tau phosphorylation, altering synapse structure and tau function. Even though the precise role of BIN1 in the neuronal tissue needs further investigation, the authors aim to throw light on the potential of BIN1 and unfold its implications on tau and Aβ pathology, to aid AD researchers across the globe to examine BIN1, as an appropriate target gene for disease management. Graphical Abstract